In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

Targeted Radiopharmaceuticals Summit US

Jul 26, 2022 - 09:00 AM - Jul 28, 06:00 PM
Hanson Wade
Embassy Suites by Hilton Boston at Logan Airport
207, Porter St

ZIP: 02128
Phone: +16174554188

Ticket Price: USD 2999.0 - USD 5197.0

The brand-new Targeted Radiopharmaceuticals US Summit (TRP US) is the only industry-led meeting dedicated to the development of next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months, with a wave of new investment in light of Lutathera's extraordinary performance.

Are you part of a pharmaceutical business aiming to have their Theranostic approved? If so, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging.

Hear the latest insights, case studies, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.

Tickets: https://go.evvnt.com/1065196-2?pid=1052
Brochure: https://go.evvnt.com/1065196-3?pid=1052

Drug Developer Pricing - Conference + 2 Workshops: USD 4197.0,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.0,
Drug Developer Pricing - Conference Only: USD 2999.0,
Standard Pricing - Conference + 2 Workshops: USD 5197.0,
Standard Pricing - Conference + 1 Workshop: USD 4498.0,
Standard Pricing - Conference Only: USD 3799.0

Speaker Details

Sarah Cheal, Assistant Professor, Weill Cornell Medical College, Alan B. Packard, Sr. Research Associate/Associate Professor, Boston Children's Hospital/Harvard Medical School, Stanley Satz, Chairman, Advanced Innovative Partners, Jarrod Longocor, Chief Business Officer, Cellectar Biosciences, Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals, Jason Dearling, Senior Director, Radiopharmacology, Curie Therapeutics, Kemp Dolliver, Senior Analyst/ Director of Research, Brookline Capital Markets, Chris Leamon, Chief Scientific Officer Fusion Pharmaceuticals, Fusion Pharmaceuticals, Peter Conti, Professor of Radiology PET Imaging Center and Director, Molecular Imaging Center, Keck School of Medicine, Manuel Bardies, Cancer Research Institute, Montpellier, France, Jason Hurt, Chief Medical Officer, Oranomed, Alexander Yordanov, Senior Radiochemist and Tech Service Lead, Progenics Pharmaceuticals, Inc., Riccardo Canevari, Managing Director and Chief Executive Officer, RadioPharm Theranostics, John Babich, President and CEO, Ratio Therapeutics, Roland Turck, Managing Partner, TurckBio, Amos Hedt, Chief Business Strategy Officer, Viewpoint Molecular Targeting, Inc, Kelly Orcutt, Senior Principal Scientist, Viewpoint Molecular Targeting Inc, Mengshi Li, Principal Scientist, Viewpoint Molecular Targeting, Inc., Geoffrey Johnson, Nuclear Medicine Specialist, Radiologist, Mayo Clinic, Luke Nordquist, Medical Oncologist and CEO/Founder, XCancer Research, Ken Song, Chairman of the Board and Founder, Rayze Bio, Oliver Sartor, Laborde Professor for Cancer Research, Medical Director Tulane Cancer Center, Associate Dean for Oncology, Tulane Medical School

Event Categories
Keywords: conference , pharmaceutical


Events Calendar

26 27 28 29 30 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6

Event Location


VIP Life Time Subscription to our Newsletters!